Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK-TKIs in ALK-rearranged Advanced Squamous Cell Carcinoma
NCT05014464Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Nov 2021
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib, alectinib, brigatinib, lorlatinib in squamous cell carcinoma of the lung (LSCC), sponsored by Hunan Cancer Hospital. Started Nov 2021; status: recruiting.
02
Drugs
crizotinibalectinibbrigatiniblorlatinib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT05014464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014464.